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Abstract
Nitric oxide (NO)-releasing chitosan oligosaccharides were modified with ester functional groups 
to examine how the mucoadhesive nature of the scaffold impacts the ability of NO to degrade 
mucins from human bronchial epithelial cell cultures and clinical sputum samples collected from 
patients with cystic fibrosis (CF). Agarose gel electrophoresis experiments indicated that the 
mucoadhesive NO-releasing chitosan oligosaccharides degraded both the purified mucins and 
sputum, while control scaffolds (without NO release or mucoadhesive ligands) had no effect on 
mucin structure. Microscopic observations of sputum treated with the mucoadhesive NO-releasing 
chitosan oligosaccharide confirmed degradation of the mucin and DNA networks. Similarly, the 
viscosity and elasticity of sputum were reduced upon treatment with the mucoadhesive NO-
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INTRODUCTION
Cystic fibrosis (CF) is a life-limiting, genetically inherited disorder affecting roughly 30,000 
people in the United States of America (US) and 70,000 people worldwide.1,2 A defect in 
the CF transmembrane conductance regulator protein results in the accumulation of mucus 
in and obstructs normal function of the lungs, liver, pancreas, gastrointestinal tract, and 
reproductive system.3 As mucus accumulates and thickens in the CF lungs, airway clearance 
is impaired, fostering bacteria colonization.4 This thickened mucus layer generates an 
environment that protects bacteria from immune cells and promotes biofilm formation.5 
Chronic infections are accompanied by persistent inflammation and ultimately a decline in 
lung function.5 As a result, respiratory complications related to chronic bacterial infections 
are the leading cause of death for CF patients.6
Many CF therapeutics have focused on treating the symptoms of the disease as it progresses, 
specifically by combating bacterial infection and reducing mucus viscoelasticity and 
accumulation. We have previously reported on the bactericidal action of NO-releasing 
chitosan oligosaccharides against CF-relevant Pseudomonas aeruginosa in planktonic and 
biofilm-based cultures.7,8 The broad spectrum antibacterial action of NO makes this 
compound an attractive alternative to traditional antibiotics for which many bacteria have 
developed resistance. The next logical step in applying NO-releasing chitosan as a CF 
therapeutic involves understanding the effects of both NO and the chitosan backbone on the 
viscoelastic properties of mucus. In addition, the role of chitosan mucoadhesion on NO 
delivery must be investigated to understand the true potential of NO-releasing chitosan 
oligosaccharides as a CF treatment candidate.
As a result of favorable properties including mucoadhesivity,9,10 biodegradability,9,11 and 
low cytotoxicity,9 researchers have begun to consider the use of chitosan for pulmonary drug 
delivery applications. The study of chitosan’s mucoadhesive properties, in particular, has 
become an active area of research. Electrostatic interaction between chitosan’s positively 
charged amines and the negatively charged sialic acid residues of mucins9,12,13 is believed to 
enhance chitosan retention in the airways and therefore increase time of action.9,14 In fact, 
chitosan has been reported to facilitate the delivery and improve the efficacy of antibiotic-
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releasing particles to the lungs.15–19 On the other hand, mucoadhesion could potentially 
affect drug penetration into the mucus. Klinger-Strobel et al. described the benefits of 
modifying chitosan with polyethylene glycol (PEG)14 to facilitate better drug action on 
human cervicovaginal mucus,20,21 bacterial biofilms,22 and CF sputum.20–23 Herein, we 
modified chitosan oligosaccharides with functional groups that would control mucoadhesive 
properties while maintaining comparable NO-release characteristics to understand the 
effects of scaffold mucoadhesion on the mucolytic action of NO.
EXPERIMENTAL SECTION
Materials
Medium molecular weight chitosan (viscosity 200–800 cP), 2-methylaziridine, ethyl 
acrylate, tert-butyl acrylate, sulfopropyl acrylate potassium salt, sodium dodecyl sulfate 
(SDS), dithiothreitol (DTT), bovine serum albumin (BSA), and type II gastric pig mucin 
(GPM) were purchased from Sigma-Aldrich (St. Louis, MO). Nitric oxide gas was 
purchased from Praxair (Sanford, NC). Argon (Ar), NO calibration (26.85 ppm, balance 
N2), and nitrogen (N2) gases were purchased from Airgas National Welders (Durham, NC). 
Sodium methoxide was purchased from Acros Organics (Geel, Belgium).
Tris-acetate-EDTA (TAE) buffer (10×) was purchased from Mediatech, Inc. (Manassas, VA) 
and diluted 1:10 in distilled water prior to use. Saline-sodium citrate (SSC) buffer (20×) was 
purchased from Promega Corporation (Madison, WI) and diluted 1:5 to obtain 4× SSC 
buffer. Dulbecco’s phosphate buffered saline (DPBS, 1×) was purchase from Life 
Technologies (Carlsbad, CA). Powdered milk (Drink ‘n Mix) was purchased from Walmart 
(Durham, NC). Neutral buffered formalin (NBF, 10 vol %) was purchased from Sigma-
Aldrich (St. Louis, MO). Phosphate buffer (10 mM, pH 6.5) and phosphate buffered saline 
(10 mM, pH 6.5) were prepared in-house using common laboratory salts and reagents.
Anti-MUC5B antibody (H-300) was purchased from Santa Cruz Biotechnology (Dallas, 
TX). Anti-MUC5AC antibody (45M1) was purchased from Abcam (Cambridge, MA). 
Secondary antibodies (IRDye 800CW Donkey anti-Mouse IgG and IRDye 680RD Donkey 
anti-Rabbit IgG) were purchased from LI-COR Biosciences (Lincoln, NE). 4′,6-
Diamidino-2-phenylindole dihydrochloride (DAPI) was purchased from Life Technologies 
(Carlsbad, CA).
Distilled water was purified using a Millipore Milli-Q UV Gradient A-10 system (Bedford, 
MA). All common laboratory salts and reagents were purchased from Fisher Scientific 
(Pittsburgh, PA). All materials were used without further purification unless specified 
otherwise.
Culture washings containing mucus were collected from primary human bronchial epithelial 
(HBE) cell cultures from a patient with CF as previously described.24 Briefly, primary cell 
cultures obtained from excess surgical tissue (UNC-Chapel Hill Tissue Core Facility) were 
grown on 0.5 mm pore-sized Millicell cell culture inserts (Millipore, Bedford, MA) in air–
liquid interface media (UNC Chapel Hill Tissue Core Facility) for a minimum of 6 weeks 
until the cultures developed cilia and well-defined periciliary liquid (PCL) and mucus layers. 
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Washings were collected by adding 150 μL of PBS per 1 cm2 of culture area after 2 d of 
mucus accumulation. Subsequently, these washings were treated immediately with chitosan 
oligosaccharides for analysis.
Sputum samples were collected from CF patients by spontaneous expectoration. The 
samples were stored in sterile containers at −20 °C until use.
Synthesis of 2-Methylaziridine Modified Chitosan Oligosaccharides
Polymeric chitosan was oxidatively degraded into chitosan oligosaccharides as described 
previously.25 Briefly, medium molecular weight chitosan (2.5 g) was dissolved in 15 wt % 
hydrogen peroxide (50 mL) and stirred at 85 °C for 1 h. Insoluble, nondegraded chitosan 
was removed by filtration. Water-soluble oligosaccharides were collected via precipitation in 
acetone, washed copiously with ethanol, and dried in vacuo. A Ubbelohde viscometer was 
used to measure the viscosity of the chitosan oligosaccharides in a solution of sodium 
chloride (0.20 M) and acetic acid (0.10 M) at 25 °C. The molecular weight was calculated to 
be 4.41 ± 0.04 kDa using the classic Mark–Houwink equation (η = 1.81 × 10−3 M0.93).26
The water-soluble chitosan oligosaccharides were then modified with 2-methylaziridine 
(Scheme 1). Chitosan oligosaccharides (0.50 g) were dissolved in stirred water (10.00 mL). 
Hydrochloric acid (12.1 M, 27.5 μL), water (250 μL), and 2-methylaziridine (178 μL, 1:1 
molar ratio to primary amines on the unmodified chitosan oligosaccharide) were then added 
to this solution, with continuous stirring for 5 d at 25 °C and 24 h at 85 °C. The resulting 2-
methylaziridine-modified chitosan oligosaccharides (COS) were precipitated in acetone, 
washed with methanol to remove excess 2-methylaziridine, and dried in vacuo.
Ester Modification of Chitosan Oligosaccharides
The mucoadhesive properties of COS were altered by the Michael addition of acrylates to 
the amino groups to form structurally distinct saturated ester functional groups on the 
scaffold backbone (Scheme 1). Ethyl acrylate (EA, 2.08 mL) and tert-butyl acrylate (TBuA, 
2.78 mL) were added to COS (500 mg) in a solution of water (6.00 mL), methanol (14.00 
mL), and ammonium hydroxide (1.00 mL). Methanol was excluded from the reaction 
solvent for the addition of sulfopropyl acrylate (SPA) because the SPA is water-soluble. 
More specifically, SPA (4.43 g) was added to COS (500 mg) in a solution of water (20.00 
mL) and ammonium hydroxide (1.00 mL). A 10-fold molar excess of acrylate (vs primary 
amine) was used for all reactions to maximize the acrylate addition. After 72 h of stirring at 
room temperature, the resulting ester-modified COS was precipitated with acetone, collected 
via centrifugation, and washed with methanol to remove excess reagent. The SPA product 
was washed copiously with ethanol. The resulting EA-, TBuA-, and SPA-modified COS 
(COS-EA, COS-TBuA, and COS-SPA, respectively) were dried in vacuo overnight and 
stored at room temperature. Removal of unreacted acrylate from the products was verified 
by the disappearance of the vinyl protons in the 1H NMR spectra. Ester-modified COS was 
characterized by 1H NMR (Bruker 400 MHz DRX spectrometer) to determine the degree of 
substitution and product purity. Representative 1H NMR peaks were as follows:
COS: 1H NMR (D2O, 400 MHz) δ-0.8–1.1 (br, 3H), 1.9 (s, 3H), 2.3–2.9 (br, 4H), 
3.3–4.0 (br, 5H), 4.4 (s, 1H).
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COS-EA: 1H NMR (D2O, 400 MHz) δ-0.8–1.1 (br, 6H), 1.9 (s, 3H), 2.3–2.9 (br, 4H), 
3.3–4.0 (br, 5H), 4.1 (s, 2H), 4.4 (s, 1H).
COS-TBuA: 1H NMR (D2O, 400 MHz) δ-0.8–1.1 (br, 12 H), 1.9 (s, 3H), 2.3–2.9 (br, 
4H), 3.3–4.0 (br, 5H), 4.4 (s, 1H).
COS-SPA: 1H NMR (D2O, 400 MHz) δ-0.8–1.1 (br, 6H), 1.9 (s, 3H), 2.3–2.9 (br, 
4H), 3.3–4.0 (br, 5H), 4.1 (s, 2H), 4.4 (s, 1H).
Calculations used to determine the degrees of deacetylation and substitution, and FT-IR 
characterization data are provided in Supporting Information.
Synthesis of NO-Releasing Chitosan Oligosaccharides
To impart NO storage and release, N-diazeniumdiolate NO donors were formed on the 
secondary amines of the COS and ester-modified COS.25 Modified chitosan 
oligosaccharides (15 mg) were dissolved in a solution of water (300 μL), methanol (700 μL), 
and 5.4 M sodium methoxide (25 μL) in a 1 dram vial equipped with a stir bar. The open vial 
was placed in a 160 mL Parr general purpose stainless steel pressure vessel and stirred 
vigorously. Oxygen was removed from the reaction vessel by purging with argon (10 s, 8 
bar) thrice, followed by three longer argon purges (10 min, 8 bar). The vessel was then filled 
with potassium hydroxide-purified NO gas (10 bar) for 72 h at room temperature. 
Afterward, the argon purging procedure was repeated to remove unreacted NO. N-
Diazeniumdolate-modified chitosan oligosaccharides (COS-NO, COS-EA-NO, COS-TBuA-
NO, and COS-SPA-NO) were precipitated in acetone, collected via centrifugation to yield a 
yellow powder, dried in vacuo, and stored at −20 °C until further study.
Chemiluminescence Detection of NO Release
A Sievers 280i Chemiluminescence Nitric Oxide Analyzer (Boulder, Colorado) was used to 
quantify NO release. Prior to analysis, the instrument was calibrated with air passed through 
a NO zero filter (0 ppm of NO) and 26.8 ppm of NO standard gas (balance N2). The N-
diazeniumdiolate modified chitosan oligosaccharides (1.0 mg) were immersed in 30 mL of 
deoxygenated PBS (pH 6.5) at 37 °C whereupon released NO was carried by N2 gas to the 
detector at a flow rate of 80 mL/min. Additional N2 flow was supplied to the sample flask at 
200 mL/min to match the collection rate of the instrument. Analysis was terminated once 
NO concentrations fell below 10 ppb NO/mg COS-NO. Additionally, a PerkinElmer 
Lambda 40 UV/vis spectrometer was used to obtain UV–vis spectra of 0.1 mg/mL solutions 
of all compounds in 50 mM sodium hydroxide. This basic solution was used in order to 
avoid undesirable N-diazeniumdiolate NO donor degradation that begins immediately at 
neutral pH.
Turbidimetric Titrations of Mucins
Gastric pig mucin (960 mg) was dissolved in 250 mL of sterile phosphate buffer (PB) at 
4 °C for 18 h. The mucin suspension was centrifuged (1,500g, 4 °C, 0.5 h) to remove 
insoluble components. The resulting mucin solution was stored in sterile containers at 4 °C 
for up to 1 week prior to use. Solutions of mucin and ester-modified chitosan 
oligosaccharides were prepared by combining 236 μL of the purified mucin solution with 34 
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μL of the chitosan oligosaccharide solutions (3.6–54.5 mg/mL in sterile PB) in a 96-well 
plate. The mucin and chitosan solutions were incubated for 1 h at 37 °C with gentle shaking 
(100 rpm) after which the absorbance was read at 540 nm using a Thermoscientific 
Multiskan EX plate reader. A corrected absorbance was obtained after subtracting the 
absorbance of the chitosan oligosaccharides (i.e., without mucin) from the COS-mucin 
absorbance.
Zeta Potentials of Mucin–Chitosan Oligosaccharide Aggregates
Gastric pig mucin (10.0 mg) was dissolved in 10.00 mL of sterile PB at 4 °C for 18 h. The 
mucin suspension was centrifuged (1,500g, 4 °C, 0.5 h) to remove insoluble components. 
The resulting mucin solution was stored in sterile containers at 4 °C for up to 1 week prior to 
use. Modified chitosan oligosaccharide solids were added to the mucin solution, vortexed 
until dissolved, and incubated for 1 h at 37 °C. Lower concentrations of mucin and chitosan 
oligosaccharides were used in this assay to prevent corrosion of the electrochemical cell for 
the zeta potential measurements. The zeta potential (i.e., surface charge) of the mucin–
chitosan aggregate was determined using a Malvern Zetasizer Nano-ZS equipped with a 10 
mW HeNe laser (633 nm) and a NIBS detector at an angle of 173°.
Gel Electrophoresis
Concentrated stocks of chitosan oligosaccharides (COS and COS-SPA) and NO-releasing 
chitosan oligosaccharides (COS-NO and COS-SPA-NO) or DTT (20 μL) were added to 
HBE mucus (40 μL), stirred gently, and incubated at room temperature for 2 h with gentle 
rocking. As CF sputum contains proteolytic enzymes, the incubation time was decreased to 
1 h to reduce enzymatic degradation of the sample.
Agarose Mucin Gel Electrophoresis
Following treatment, samples were separated by electrophoresis as previously described.27 
In brief, samples (40 μL) were loaded onto a 0.8 wt % agarose gel in 1× TAE buffer with 1 
wt % SDS for electrophoretic mucin separation at 80 V for 90 min. The gel was 
subsequently reduced with 10 mM DTT for 20 min. Mucins were transferred by vacuum (45 
mbar, 1.5 h) in 4× SSC buffer onto a nitrocellulose membrane with a pore size of 0.45 μm 
(Optitran BA-S 85 membrane, GE Healthcare Life Sciences, Piscataway, NJ). Following 
blocking of nonspecific interactions with powdered milk (3 wt % in DPBS) for 1 h, mucins 
were detected by exposure to diluted primary antibodies raised against MUC5AC and 
MUC5B (0.1 μg/mL in 3% milk) overnight (3 °C). The membranes were washed thrice with 
DPBS (10 min) and fluorescently labeled with secondary antibodies (0.2 μg/mL in 3 wt % 
powdered milk, 1 h, 25 °C). The gels were subsequently washed in DPBS again and then 
analyzed using a LI-COR Odyssey CLx Infrared Imaging System (LI-COR Biosciences, 
Lincoln, NE). Migration distances were quantified using ImageJ (National Institute of 
Health, Bethesda, MD). For CF sputum samples, migration distances were normalized to the 
PBS-treated sample to account for the large degree of heterogeneity.
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Prior to loading onto the agarose gel, CF sputum samples (5 μL) exposed to COS, COS-NO, 
COS-SPA, or COS-SPA-NO were carefully smeared on glass microscopy slides to prevent 
mechanical disruption of mucin and the DNA network. The samples were fixed with NBF 
(10 vol %), washed with DPBS, and blocked with BSA (3 wt % in DPBS) for 1 h at room 
temperature. Mucin networks were visualized by immunohistochemical detection. First, 
MUC5AC and MUC5B were identified via exposure to primary antibody solutions (0.4 and 
0.2 μg/mL for mouse anti-MUC5AC and rabbit anti-MUC5B, respectively). The slides were 
washed with DPBS three times (10 min) prior to exposure to secondary antibodies (1 μg/mL 
Alexa 488 and 594 antirabbit and mouse, respectively) and DAPI (5 μg/mL) for 1 h at 25 °C 
to facilitate quantitative measurement. The slides were then washed with DPBS (10 min) 
and mounted with Fluorsave (Calbiochem). Confocal images were obtained with an 
Olympus FV 1000 (Olympus, Hamilton, Bermuda) using a 20× objective.
Parallel Plate Rheology
Spontaneously expectorated sputum from one CF patient collected at a single time point was 
used for rheological measurements. Concentrated solutions of COS-NO (27.8 μL) were 
added to 250 μL aliquots of sputum to achieve final COS-NO concentrations of 0, 5, 10, and 
20 mg/mL. Sputum samples were slowly rotated at room temperature for 1 h. The 
rheological properties of the treated samples were measured via amplitude sweep 
experiments over a stress range of 0.025–50 Pa at a single frequency (1 Hz) on a Bohlin 
Gemini Rheometer (Malvern Instruments, Worcestershire, UK) with a 20 mm diameter 
parallel plate set to a gap thickness of 50 mm. Rheological measurements were performed at 
23 °C to minimize sample dehydration. The elastic modulus (G′) and viscous modulus (G″) 
were determined from the linear regimes as previously reported.28 All values are reported as 
the mean ± standard error of the mean (SEM) for a minimum of three separately evaluated 
aliquots of the treated sputum sample.
Statistical Analysis
All values are reported as the mean ± standard deviation for three or more pooled 
experiments unless otherwise noted. Statistical significance was determined using the two-
tailed Student’s t test.
RESULTS AND DISCUSSION
Synthesis of NO-Releasing Mucoadhesive Chitosan Oligosaccharides
The mucoadhesive nature of chitosan is believed to be derived from electrostatic and 
hydrophobic interactions as well as hydrogen bonding between chitosan and mucins. Of 
these interactions, electrostatic attractions between the positively charged primary amine on 
chitosan and the negatively charged sialic acid and ester sulfate groups on mucins 
predominate.13 Sogias et al.13 and Mencchicchi et al.12 have demonstrated that blocking the 
primary amines on chitosan with acetyl groups (i.e., decreasing the deacetylation of the 
chitosan) reduces its ability to bind and aggregate mucin in solution. To determine how 
chitosan mucoadhesion affects NO delivery and efficacy, three structurally distinct ester 
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modifications were used to sterically block the primary amines on 2-methylaziridine-
modified chitosan oligosaccharides (COS) (Scheme 1). Acrylates were chosen as the route 
to modification because propenoates covalently bind to chitosan under mild synthetic 
conditions. Specific modifications were also selected based on their commercial availability. 
Ethyl acrylate and tert-butyl acrylate were compared to determine if increasing the steric 
bulk from an ethyl group to a tert-butyl group altered the mucoadhesive nature of COS. To 
reduce mucoadhesion, a negatively charged acrylate (sulfopropyl acrylate) was employed to 
electrostatically repel mucus in addition to sterically hindering the primary amine. Reaction 
conditions for the Michael addition of acrylates to the COS scaffold were optimized to 
maximize modification efficiency. All reactions were carried out at room temperature as 
heating to 50 °C produced undesirable side-reactions between ethyl acrylate and the chitosan 
backbone (data not shown). The primary amine on COS (RNH3+, pKa ∼ 10) is deprotonated 
in basic solution (pH 12), thereby increasing reactivity toward the β-carbon of the acrylate 
vinyl group. In this manner, the modification of COS with TBuA is enhanced from 11 ± 1% 
at pH 7 (i.e., neutral conditions) to 83 ± 15% at pH 12. The resulting, optimized reaction 
yielded similar modification efficiencies for all three ester modifications: 86 ± 4% for COS-
EA, 83 ± 15% for COS-TBuA, and 98 ± 15% for COS-SPA. Differences between 
modification efficiencies for the three distinct saturated ester groups were not significant as 
determined by one-way ANOVA (F (2,10) = 1.42, p = 0.31).
To impart NO storage and release, N-diazeniumdiolate NO donors were formed at the 
secondary amine sites on the modified chitosan oligosaccharides via exposure to high 
pressures of NO gas.25 Nitric oxide storage was tuned by maintaining constant solvent ratios 
(3:7 water/methanol) and base concentrations for all scaffolds, resulting in similar NO 
payloads ([NO]total ∼ 0.4 μmol/mg) and release kinetics (t1/2 ∼ 30 min) for both the 
unmodified COS and ester-modified scaffolds (Table 1). A sample NO-release curve can be 
found in the Supporting Information. While NO release from N-diazeniumdiolates may be 
altered by charge stabilization or hydrophobicity imparted from local functional groups,29 
the comparable NO-release kinetics of these materials were somewhat expected as the ester 
modifications did not significantly alter the hydrophobicity of the materials. Indeed, the 
similar NO-release half-lives exhibited herein indicate that the NO-release kinetics of ester-
modified chitosan oligosaccharides are generally more influenced by the hydrophobicity of 
the chitosan backbone rather than the exterior functional groups.
The formation of the N-diazeniumdiolate NO donor was characterized using UV–vis 
spectroscopy. For all compounds, UV–vis spectra showed an absorbance maximum at 253 
nm following exposure to high pressures of NO gas, confirming N-diazeniumdiolate NO 
donor formation.30 Absorbance peaks at or near 350 nm were not observed, indicating little 
or no formation of potentially carcinogenic nitrosamines.31 The absorbance spectra for each 
of the modified chitosan oligosaccharides are provided in the Supporting Information.
Mucoadhesion of Saturated Ester- and 2-Methylaziridine-Modified Chitosan 
Oligosaccharides
Turbidimetric titrations of gastric pig mucin (GPM) with ester-modified COS were 
performed to determine the mucoadhesive properties of the chitosan oligosaccharide 
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scaffolds. In the presence of low concentrations of mucoadhesive polymers, mucins form 
light scattering self-assembled complexes.13,32,33 As such, the turbidity of mucin solutions 
(as measured by corrected absorbance) is expected to increase with the addition of 
mucoadhesive scaffolds, resulting in increased absorbance measurements. At larger 
concentrations, mucoadhesive polymers have been shown to disaggregate mucin–polymer 
complexes.13 Alternately, the turbidity (i.e., absorbance) of mucin solutions should remain 
constant in the presence of muco-inert scaffolds. Turbidity was monitored at 540 nm to 
maximize sensitivity toward GPM-chitosan complexes while minimizing the absorbance of 
free chitosan oligosaccharides in solution (λmax = 375 nm).
The turbidity of GPM solutions increased rapidly (nearly 4-fold) at low concentrations (≤3 
mg/mL) of the COS, COS-EA, and COS-TBuA scaffolds, indicating significant 
mucoadhesion with mucins in solution (Figure 1). At concentrations ≥4.5 mg/mL, 
disaggregation of chitosan mucin complexes was observed for COS and COS-TBuA. The 
addition of COS-SPA to GPM solutions resulted in a slight increase in the turbidity of the 
solutions at high concentrations. As electrostatic interactions between the positively charged 
chitosan and negatively charged mucins facilitate mucoadhesion,12,13,34 the corresponding 
electrostatic repulsion between the mucins and negatively charged sulfonate group of COS-
SPA likely circumvented the formation of chitosan–mucin aggregates at low concentrations. 
At larger concentrations (>3 mg COS-SPA/mL), small increases in turbidity were observed 
and attributed to the attractive forces (e.g., hydrophobic or hydrogen bonding) between the 
chitosan oligosaccharide backbone and mucin particles.13
While the TBuA and EA modifications were expected to sterically block the mucoadhesive 
primary amines on the COS scaffold, any steric hindrance did not significantly alter the 
mucoadhesion compared to the unmodified COS scaffold. The retained mucoadhesive 
properties are likely the result of insufficient steric blocking of the positively charged amine 
or hydrophobic interactions between the modified group and the mucins. To determine the 
extent of mucoadhesion due to electrostatics, the turbidity assay was repeated in PBS 
(Supporting Information). The addition of sodium chloride to the solution minimizes 
electrostatic interactions between chitosan and mucins.13 For all modified chitosan 
oligosaccharides, the addition of sodium chloride reduced the turbidity of the solutions, 
indicating that electrostatic attraction between the chitosan oligosaccharides and mucins was 
retained even after the chitosan was modified to prevent interactions between the positively 
charged amine and negatively charged groups on the mucins.
Zeta potential measurements of chitosan–mucin aggregates corroborated the turbidimetric 
titration results (Figure 2). At pH 6.5, blank GPM solutions exhibited a zeta potential of −9.8 
± 0.5 mV. Adding chitosan oligosaccharides modified with neutral or positively charged 
terminal groups (COS, COS-TBuA, and COS-EA) to dilute mucin solutions resulted in 
increased zeta potentials. Treatment of GPM solutions with negatively charged COS-SPA 
did not alter the measured zeta potential at the concentrations tested, further demonstrating 
the reduced mucoadhesive properties of COS-SPA. Only low concentrations of chitosan 
oligosaccharide could be tested in this assay because larger concentrations corroded the 
electrode on the zeta potential cell.
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Electrophoretic Separation of Purified Mucus Following Treatment with Chitosan 
Oligosaccharides
To determine the effects of NO on mucin size (i.e., molecular weight), mucus collected from 
CF HBE cultures was separated by agarose gel electrophoresis following treatment with 
increasing concentrations of control chitosan scaffolds (i.e., non-NO-releasing) and NO-
releasing chitosan oligosaccharides. The mucolytic action of the NO-releasing chitosan 
oligosaccharides was evaluated using both MUCB and MUC5AC, the key mucins 
responsible for gel formation in the airway. The concentrations of these mucins are known to 
increase during pulmonary exacerbations in CF.35 Strongly and weakly mucoadhesive 
chitosan oligosaccharides (COS and COS-SPA, respectively) were used to evaluate the 
effects of scaffold mucoadhesion on mucin migration. These modifications were chosen 
because the difference in the charge of their terminal functional groups (NH3+ for COS and 
SO3− for SPA) were hypothesized to cause differences in their interactions with negatively 
charged mucins. Any increase in the mucin migration distance after exposure to chitosan 
oligosaccharides would reflect a change in size and/or charge of the mucin multimers, 
suggesting a beneficial therapeutic effect in the treatment of CF mucus.
Compared to treatment with blank PBS, mucin migration was not affected by exposure to 
control COS and COS-SPA scaffolds regardless of the scaffold’s mucoadhesive properties 
(Figure 3). Treatment with the weakly mucoadhesive NO-releasing COS-SPA (COS-SPA-
NO) scaffold similarly had no impact on mucin migration. However, treatment with the 
strongly mucoadhesive COS-NO increased the migration distances of both MUC5AC and 
MUC5B mucins relative to controls (p ≤ 0.05) in a dose-dependent manner at 10 mg/mL 
(Figure 4). The increase in mucin migration may be attributed exclusively to the 
pharmacological effects of NO since treatment with the control scaffold alone did not affect 
migration. In this manner, the reduced size of the mucin multimers leads to faster migration. 
Of note, scaffold mucoadhesion is necessary for effective NO delivery as treatment with 
COS-SPA-NO did not alter the migration of MUC5AC or MUC5B. We hypothesize that 
poor scaffold-mucin association with negatively charged COS-SPA does not facilitate 
localized NO release, thereby requiring greater doses for equivalent therapeutic activity. We 
have reported similar observations for bacteria and NO-releasing silica and dendrimer 
macromolecular scaffolds.36 Indeed, the association of dendrimers37–39 and silica40–43 with 
bacteria membranes improve the antimicrobial action of NO release as a result of more 
targeted and localized NO delivery. Clearly, the design of mucoadhesive NO-releasing 
scaffolds would be equally advantageous for ensuring target proximity and increased 
therapeutic action.
Electrophoretic Separation of CF Sputum Following Treatment with Chitosan 
Oligosaccharides
While NO released from COS-NO increased the migration of polymeric mucins, the 
complexity of CF sputum (e.g., high concentrations of DNA, bacteria, inflammatory 
proteins, and cells) may influence NO delivery and potency. We thus evaluated the effects of 
COS, COS-NO, COS-SPA, and COS-SPA-NO on mucins in CF sputum via agarose gel 
electrophoresis. As with HBE mucus, treatment of CF sputum with control (non-NO-
releasing) chitosan scaffolds and COS-SPA-NO did not affect mucin migration (Figure 5). In 
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contrast, migration of MUC5AC and MUC5B increased following treatment with COS-NO 
at concentrations ≥ 10 mg/mL (Figure 6), further supporting the mucolytic activity of NO 
for this NO-release scaffold. Of note, the concentration of chitosan oligosaccharides used in 
this assay is higher than the concentration used in the turbidity assay. The concentration of 
mucins is also higher in the sputum (approximately 6.5 mg/mL)44 than the mucin 
concentration used in the turbidity assay (3.0 mg/mL); however the ratio of chitosan to 
mucin (mg/mg) is similar in both assays. Others have argued that muco-inert scaffolds are 
more effective for drug delivery in CF airways due to improved mucus penetration.14 
However, the pharmacological target of many such drugs lies beyond the mucus layer, 
whereas COS-NO targets the accumulated, adherent mucus itself. Indeed, the mucolytic 
activity of NO-releasing chitosan oligosaccharides appeared to be dependent upon the 
mucoadhesive properties of the COS scaffold for both HBE mucus and CF sputum, with the 
weakly mucoadhesive COS-SPA-NO scaffold demonstrating no beneficial therapeutic effect.
Fluorescent Microscopy of the CF Sputum
To visualize NO-mediated changes in the network formed by mucins and DNA in the CF 
sputum, treated samples were imaged with a confocal laser scanning microscope. In the 
PBS-treated samples (Figure 7A–D), networks of MUC5AC (red) and MUC5B (green) were 
intertwined, forming three-dimensional architectures characterized by thick mucin filaments 
(Figure 7A, white arrows) and web-like mucin sheets. As detected by intense DAPI (blue) 
staining, intact neutrophils were also embedded within the three-dimensional mucin 
network. Upon treatment with chitosan oligosaccharides, the intracellular DNA signal was 
diminished while the extracellular signal was enhanced throughout the sputum samples, 
likely the result of neutrophil and other inflammatory cell death (Figure 7F, J, N, and R).45 
Treatment with COS-SPA and COS-SPA-NO had no other discernible effects on the CF 
sputum architecture.
The positively charged chitosan variants, COS and COS-NO, greatly altered the appearance 
of the mucin networks in CF sputum. The COS control alone induced mucin clustering as 
evidenced by both signal intensification and size reduction of the mucin sheets (Figure 7E, 
white arrows), indicating that the COS-mucin electrostatic interactions persisted in the 
complex viscoelastic environment of CF sputum. Nitric oxide release via COS-NO further 
degraded the mucin network, as depicted by a lower overall mucin signal and relaxed mucin 
network (Figure 7K,L). Samples treated with COS-NO (Figure 7 K–L) lacked the long 
filaments of mucin that were abundant in the PBS-treated samples (Figure 7A, white 
arrows). These microscopic observations suggest intense disruption of the mucin network by 
COS-NO. The NO-mediated mucin disentanglement is expected to reduce sputum elasticity 
since high mucin entanglement correlates with elevated sputum elasticity.5
Treatment with COS-SPA-NO did not alter the sputum network (Figure 7Q–T). Electrostatic 
repulsion between the chitosan oligosaccharide backbone and negatively charged mucins 
prevented effective chitosan oligosaccharide penetration into the most dense mucin matrix. 
In this manner, the NO release from COS-SPA-NO was ineffective at altering the mucin 
network.
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Mucolytics are designed to decrease the biophysical properties of mucus, thereby increasing 
mucociliary clearance and pulmonary function.44,46 Parallel plate rheology was used to 
measure both the elastic (G′) and viscous (G″) moduli, and evaluate how treatment with 
COS-NO affected the biophysical properties of CF sputum. After treatment with COS-NO 
for 1 h at room temperature, dose-dependent reductions in CF sputum viscosity and 
elasticity were observed relative to controls (Figure 8). At the lowest concentration tested (5 
mg/mL), COS-NO reduced sputum elasticity and viscosity by 74.9 ± 0.4 and 66.3 ± 1.2%, 
respectively, compared to PBS-treated controls. Treatment of the CF sputum with a 4× 
concentration of COS-NO (20 mg/mL) reduced the sputum elasticity and viscosity by 93.4 
± 0.7 and 87.0 ± 2.0%, respectively. These results indicate that COS-NO is highly effective 
at decreasing the viscoelastic properties of CF sputum at short (1 h) exposure periods.
While it is difficult to compare rheological data in the literature due to widely varying 
exposure and measurement parameters,47 the COS-NO treatment resulted in similar changes 
in sputum viscoelasticity as conventional mucolytic therapies used to treat CF (e.g., N-
acetylcysteine, dornase alfa). For example, Seagrave et al. reported that N-acetylcysteine 
treatment (30 μM) for 24 h decreased the viscosity and elasticity of HBE mucus by an order 
of magnitude versus controls.28 Shah et al. observed reduced expectorated sputum viscosity 
and elasticity (59 and 68%, respectively) in patients with CF following treatment with 
dornase alfa for 10 d (2.5 mg, twice daily).48 While slightly greater concentrations of COS-
NO were required to similarly alter sputum rheological properties relative to the N-
acetylcysteine and dornase alfa used previously, longer exposure times and/or greater NO 
payloads would decrease the required therapeutic dose for equivalent action. Indeed, we 
employed a shorter therapeutic exposure compared to that in previous reports (1 h compared 
to 24 h28 or 10 daily treatments48) and achieved similar reductions in CF sputum viscosity 
and elasticity, demonstrating the utility of COS-NO as a potential mucolytic agent.
The diminished elastic and viscous moduli of CF sputum may also be attributed to 
alterations in the DNA network via NO-mediated DNA cleavage.49–51 Importantly, the 
electrophoretic separation and confocal microscopy results indicate that NO actively alters 
the mucin network. Studies are underway to determine the mechanism by which the NO 
alters the rheological properties of the sputum.
While these studies clearly indicate the mucolytic action of nitric oxide-releasing scaffolds, 
several questions remain for further development of any potential therapeutic. As NO may 
be genotoxic,52 the cyto- and genotoxicity of these materials should be characterized prior to 
clinical studies. Likewise, NO-release kinetics may similarly alter the mucolytic potential 
similar to how it influences antibacterial action.25,36,53
CONCLUSIONS
Herein, we report the mucolytic action of NO-releasing chitosan scaffolds as a means to 
decrease the viscoelasticity of CF sputum by reducing mucin size and damaging the three-
dimensional mucin network. While inhalation of NO gas has been proposed as a mucolytic 
therapy previously, our work establishes the potential benefits of NO release from a 
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mucoadhesive scaffold for direct delivery into the mucus plug. In all experiments, the 
mucoadhesive properties of the chitosan oligosaccharide scaffolds significantly enhanced 
NO’s potency. The ability to target NO release to CF mucus should lower the required NO 
dose for therapeutic action while simultaneously lessening any potential effects on other 
NO-mediated processes. As NO is also a potent antibacterial agent,7,8,25,36,54–56 this work 
suggests the dual-action potential of NO-releasing chitosan oligosaccharides as antibacterial 
and mucolytic agents for the treatment of CF.
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Refer to Web version on PubMed Central for supplementary material.
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Turbidimetric titration of gastric pig mucin (GPM) with modified chitosan oligosaccharide 
scaffolds without NO in phosphate buffer (10 mM, pH 6.5).
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Zeta potential measurements of gastric pig mucin (GPM)-chitosan aggregates formed upon 
the addition of chitosan oligosaccharides (without NO) to mucin solutions (1 mg/mL in 10 
mM PB at pH 6.5).
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Representative Western blot of MUC5AC and MUC5B mucins from HBE culture washings 
from a donor with cystic fibrosis treated with COS, COS-NO, COS-SPA, and COS-SPA-NO 
for 2 h at 25 °C at concentrations ranging from 0 to 20 mg/mL.
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Migration distances of (A) MUC5AC and (B) MUC5B mucins from CF-HBE culture 
washings following treatment with modified chitosan oligosaccharides for 1 h at room 
temperature. The migration distances of mucin treated with equal volumes of PBS are 
denoted with dashed horizontal lines. All values are presented as the mean ± standard 
deviation for 3 or more pooled experiments. Asterisks (*) indicate significant differences (p 
< 0.05) relative to treatment with PBS (0 mg/mL).
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Representative Western blot of MUC5AC mucins from CF sputum treated with COS, COS-
NO, COS-SPA, and COS-SPA-NO for 1 h at 25 °C at concentrations ranging from 0 to 20 
mg/nL. Similar trends were observed for MUC5B.
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Relative migration distances of (A) MUC5AC and (B) MUC5B mucins from CF sputum 
following treatment with modified chitosan oligosaccharides for 1 h at room temperature. 
Migration distances were normalized to CF sputum samples treated with an equal volume of 
PBS. All values are presented as the mean ± standard deviation for n = 3 or more pooled 
experiments.
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Confocal microscopy images of CF sputum treated with PBS (A–D) or 20 mg/mL COS (E–
H), COS-NO (I–L), COS-SPA (M–P), or COS-SPA-NO (Q–T) for 1 h at 25 °C. Arrows 
indicate long strands of mucins in untreated samples (A) which aggregate and form clumps 
upon treatment with COS (E).
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(A) Elastic and (B) viscous moduli of CF sputum following treatment with COS-NO for 1 h 
at 25 °C. Values presented as the mean ± standard error of the mean for n = 3 triplicate 
measurements. Asterisks (*) indicate significant differences (p < 0.05) relative to treatment 
with PBS (0 mg/mL).
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Chitosan Oligasaccharide Modification with 2-Methylaziridine and Subsequent 
Functionalization with Acrylates
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Table 1
NO-Release Properties of Ester-Modified Chitosan Oligosaccharides PBS (pH 6.5, 37 °C)a
[NO]totalb (μmol/mg) [NO]maxc (ppb/mg) t(l/2)d (min) tde (h)
COS-NO 0.44 ± 0.11 2800 ± 600 36.1 ± 2.8 7.85 ± 0.75
COS-EA-NO 0.42 ± 0.16 3200 ± 1100 28.8 ± 5.2 7.62 ± 0.67
COS-TBuA-NO 0.42 ± 0.09 2500 ± 400 25.3 ± 8.6 7.74 ± 0.74
COS-SPA-NO 0.39 ± 0.12 3300 ± 1100 28.9 ± 4.3 6.72 ± 1.92
a
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